Research programme: cystinuria therapeutics - Spyre Therapeutics
Alternative Names: AEB-5100; Cystinase - Spyre TherapeuticsLatest Information Update: 26 Dec 2023
At a glance
- Originator Aeglea Biotherapeutics
- Developer Spyre Therapeutics
- Class Enzymes; Recombinant proteins
- Mechanism of Action Enzyme replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cystinuria; Metabolic disorders
Most Recent Events
- 28 Feb 2023 Preclinical trials in Cystinuria in USA (Parenteral) (Aeglea Biotherapeutics pipeline, February 2023)
- 28 Feb 2023 Preclinical trials in Metabolic disorders in USA (Parenteral) (Aeglea Biotherapeutics pipeline, February 2023)
- 28 Feb 2023 Early research is ongoing the USA (Aeglea Biotherapeutics pipeline, February 2023)